Option chain shows key data for Cartesian Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cartesian Therapeutics.

Cartesian Therapeutics (NASDAQ:RNAC) Stock, Option Chain

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Nio Photo by Sundry Photography on Shutterstock

News

Intraday Update

Markets

Movers

Trading Ideas

$BTC

ANVS

APLD

BTDR

CNSP

CSTL

EHGO

INSG

IREN

JEWL

KOSS

MARA

MDWD

MESO

PRTG

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RILY

RNAC

RYDE

SHPW

SIRI

SISI

SPWR

STSS

XPEV

ZAPP

ZCAR

ZONE

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday&#39;s session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 

Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Health care cost illustration

Biotech

Equities

Health Care

Financing

Offerings

General

Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant improvements in MG Composite scores with a favorable safety profile. The therapy achieved its primary endpoints.

Cartesian&#39;s Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M

Earnings

Upgrades

Small Cap

Analyst Ratings

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

What Makes Cartesian Therapeutics, Inc. a New Buy Stock

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

On December 20, 2024, Superior Group of Companies, Inc. (the "Company") entered into a 10b5-1 trading plan (the "Plan") for the purpose of repurchasing up to $2,580,000.00 in shares of the Company's outstanding common stock (the "Repurchase Limit") in accordance with the previously-announced share repurchase program authorized by the Company's Board of Directors on August 9, 2024. The Plan is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The Plan allows the Company to repurchase shares up to the Repurchase Limit commencing December 20, 2024 and ending on the earlier of the date on which the Repurchase Limit is reached, March 13, 2025, or other events specified in the Plan. Repurchases of common stock under the Plan will be administered through an independent broker and are subject to certain price, market, volume and timing constraints specified in the Plan.

Buybacks

Superior Group Announces Trading Plan For $2.58M Stock Buyback, Effective December 20 To March 13, 2025

WIIM

TRAW

Traws Pharma shares are trading higher after they announced progress in the development of Tivoxavir Marboxi.

Our plants around the world are regularly inspected by health authorities to ensure compliance with the various markets we serve. Following an inspection by the U.S. FDA at our oral finished dose manufacturing facility in Indore, India earlier this year, the Agency has issued a Warning Letter, and an Import Alert related to this facility.
The Import Alert affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted. It makes exceptions, subject to certain conditions, for four products based on shortage concerns. There could be the potential for additional exceptions based on further discussions with the Agency.
Following the substance of FDA's original inspection observations, we immediately implemented a comprehensive remediation plan at the site. The necessary corrective and preventive actions are well underway, including but not limited to related personnel actions. Additionally, we have engaged independent third-party subject matter experts to support the remediation plan.
We have been in regular communication with FDA during this process and will continue to work to ensure that the Agency is satisfied with the steps we have taken to resolve all the points raised. Our response to the Warning Letter and Import Alert will be submitted within the required time periods.
At this time, we do not anticipate these actions impacting our current 2024 financial guidance ranges. We will incorporate&nbsp;potential future financial impact&nbsp;in our 2025 guidance ranges when we provide these in early 2025.
We take very seriously our continued and comprehensive oversight of our entire manufacturing network. Patient safety remains our primary and unwavering focus. We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve.

Global

VTRS

Viatris Issues Statement Regarding Receipt Of Warning Letter And Import Alert For Indore, India Facility; The Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into The U.S. Until The Warning Letter Is Lifted

Citigroup analyst Gabriel Barra reinstates Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) with a Buy and announces $19 price target.

Price Target

Initiation

CSAN

Citigroup Reinstates Buy on Cosan, Announces $19 Price Target

ALNY

GIVLAARI Gains Nationwide Reimbursement In Canada For Treating Acute Hepatic Porphyria

PLYA

Playa Hotels & Resorts shares are trading higher after Hyatt Hotels disclosed it executed an exclusivity agreement to potentially acquire the company.

AILE

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

OMIC

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>, LUNRW))) ("Intuitive Machines" or the "Company"), a space exploration, infrastructure, and services company, has secured additional contracts from NASA's Near Space Network ("NSN") for Direct-to-Earth ("DTE") services. These contracts further position Intuitive Machines as a vital partner in supporting NASA's missions to the Moon, and beyond.
DTE communication and navigation services are critical for enabling missions to exit Earth's orbit, reach lunar destinations, and explore deep space. The new contract awards include:
<ul>
<li>Subcategory 1.2: DTE Geostationary ("GEO") to Cislunar DTE Services, offering enhanced data transmission capabilities and autonomous operations.</li>
<li>Subcategory 1.3: xCislunar DTE Services, addressing mission needs for highly elliptical orbits and deep space operations.</li>
</ul>
Both contracts are firm-fixed-price, indefinite-delivery/indefinite-quantity task orders designed to bolster NASA's Lunar Exploration Ground Segment. These awards add capacity to alleviate demand on the Deep Space Network and support unique mission requirements.

Contracts

LUNR

Intuitive Machines Has Secured Additional Contracts From Nasa's Near Space Network For Direct-to-Earth Services

Ocean Power Technologies, Inc. (NYSE:<a href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has finalized the main assembly of the previously announced PowerBuoy&#xAE; for Naval Postgraduate School. The full system, which includes installing AT&amp;T&#xAE; 5G technology and integrating advanced subsea sensors into a PowerBuoy&#xAE; equipped with OPT's latest Merrows&#x2122; suite for AI capable seamless integration of Maritime Domain Awareness (MDA) across platforms, is now being readied for shipment ready for deployment in early 2025 alongside the Technology Showcase NPS is hosting in January. Once deployed, the PowerBuoy&#xAE; will provide continuous, autonomous monitoring and data collection capabilities in one of the world's most strategically significant maritime environments. This is another step forward in executing the Company's robust strategic plan.

OPTT

Ocean Power Technologies Readies Shipment Of AI Capable Merrows PowerBuoy For Naval Postgraduate School

Meeting Minimum Bid Price And Stockholders' Equity Requirements; Common Stock To Continue Trading On Nasdaq Capital Market

ENSC

Ensysce Biosciences Regains Full Nasdaq Compliance

Canaccord Genuity analyst Austin Moeller maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $16 price target.

EVTL

Canaccord Genuity Maintains Buy on Vertical Aerospace, Maintains $16 Price Target

WISA

WiSA Technologies Stockholders Approve Acquisition Of Data Vault Assets Valued At $266M-$501M; Deal Includes 40M Shares And $10M Note, Transforming Into Datavault Inc. With Blockchain, AI, And Web 3.0 Solutions Across Multiple Industries

New Fortress Energy shares are trading higher after Stifel maintained a Buy rating and raised its price target from $16 to $17.

iHeartMedia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHRT#NASDAQ">IHRT</a>) ("iHeartMedia" or the "Company") today announced the successful completion of its previously announced comprehensive exchange transactions of iHeartCommunications, Inc.'s ("iHeartCommunications") outstanding 6.375% Senior Secured Notes due 2026 (the "2026 Secured Notes"), 5.25% Senior Secured Notes due 2027 (the "2027 Secured Notes"), 4.75% Senior Secured Notes due 2028 (the "2028 Secured Notes"), 8.375% Senior Notes due 2027 (the "Unsecured Notes") and senior secured term loans due 2026 (the "Existing Term Loans") (collectively, the "Existing Debt") for new 9.125% Senior Secured First Lien Notes due 2029, 7.750% Senior Secured First Lien Notes due 2030, 7.000% Senior Secured First Lien Notes due 2031, 10.875% Senior Secured Second Lien Notes due 2030 and senior secured first lien term loans due 2029, respectively, in each case issued by iHeartCommunications (collectively, the "Exchange Offers").
Approximately $4.8 billion (or 92.2%) of the aggregate principal amount of the Existing Debt participated in the Exchange Offers, which expired at 9:00 a.m., New York City time, on December 18, 2024 (the "Expiration Time").

IHRT

iHeartMedia Completes Debt Exchange Offers, Reduces Debt by $440M, Extends Maturities by 3 Years, $4.8B (92.2%) of Existing Debt Participated, Strengthens Capital Structure with New Senior Secured Notes and Loans Due 2029-2031

<a href="https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true</a>

MetLife Nearing $1.4B Deal To Acquire PineBridge Excluding China Assets; Announcement Expected Monday, Valuing $100B AUM Outside China At $1.3B-$1.4B

Sky Harbour Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>, SKYH WS))) (&quot;SHG&quot; or the &quot;Company&quot;), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, announced it has completed the second closing of its previously announced equity raise. The Company issued an additional 3,955,790 PIPE shares of its Class A Common Stock in connection with the exercise of all the rights to purchase additional shares provided to PIPE investors who participated in the first closing for net proceeds of approximately $37.6 million, at a sale price of $9.50 per share. Aggregate proceeds from both closings were approximately $75.2 million, representing the full capacity of the equity raise.

SKYH

Sky Harbour Completes Second Closing Of Equity Raise, Issuing 3.96M PIPE Shares At $9.50 Each For $37.6M; Total Proceeds From Both Closings Reach $75.2M

Elon Musk&#8217;s artificial intelligence company, xAI, is testing a standalone Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iOS app&nbsp;for its chatbot, Grok.
Grok was now available only to users of Musk-owned X (formerly Twitter Inc).
The app can access real-time data from the web and X and offers generative AI features like rewriting text&nbsp;and generating images&nbsp;<a target="_blank" href="https://apps.apple.com/au/app/grok/id6670324846" rel="noreferrer noopener">from text prompts</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42613368/broadcom-expects-decade-long-ai-chip-boom-as-big-tech-invest-billions" rel="noreferrer noopener">Broadcom Expects Decade-Long AI Chip Boom as Big Tech Invest Billions</a>
xAI is also preparing a site, Grok.com, to make the chatbot accessible on the web, TechCrunch <a target="_blank" href="https://techcrunch.com/2024/12/22/xai-is-testing-a-standalone-ios-app-for-its-grok-chatbot/" rel="noreferrer noopener">reports</a>.
Grok was previously available only to X&#8217;s paying subscribers. In November, the company&nbsp;started testing a free chatbot version and rolled it out to&nbsp;all users earlier this month.
The company&#8217;s chatbot image generator model allows users to create images using pictures of public figures and copyrighted material.
xAI has reportedly reached a <a target="_blank" href="https://www.benzinga.com/startups/24/11/42235738/in-just-16-months-elon-musk-achieved-with-xai-what-took-openai-nearly-nine-years-to-accomplish" rel="noreferrer noopener">$50 billion valuation</a> just 16 months after its July 2023 founding, surpassing the billionaire&#8217;s spending on acquiring Twitter.
OpenAI, one of the most recognized names in artificial intelligence, took over nine years to reach its current valuation of $157 billion.
Reportedly, xAI is rapidly gaining momentum in the competitive AI market, now valued higher than rivals like Anthropic, worth $19 billion, and Perplexity, valued at $2.8 billion.
xAI achieved significant milestones by securing $5 billion in its latest funding round to acquire 100,000 Nvidia chips.
These chips will drive the Memphis supercomputer, a facility built to advance the company&#8217;s AI capabilities and bolster Tesla&#8217;s Full Self-Driving (FSD) technology.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Media

AAPL

AMZN

MSFT

NVDA

Elon Musk's xAI To Expand With New Chatbot App

Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, electric scooters, and related accessories, today announced that its flagship e-bike model, the Fly-11 PRO, has been officially selected by the New York City Department of Transportation ("NYC DOT") as the official e-bike for the E-Bike Trade-In Program (the "Program"). NYC DOT expects to distribute approximately 400 e-bikes during the pilot period.

FLYE

Fly-E Group Selected As The Official E-Bike Provider For NYC DOT's Trade-In Program

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) show strong fundamentals, but the trader community remains hesitant about their potential to outperform <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42535162/hyperliquid-emerges-as-ethereum-solana-rival-heres-how-high-hype-could-go">other trending cryptocurrencies</a>.
What Happened: Shibburn data shows 6.02 million SHIB tokens burned in the past 24 hours, driving the burn rate up by 661.7%. 
Key transactions included burns of 3.5 million and 2.3 million SHIB, signaling increased on-chain activity.
Shibarium&#8217;s December 2024 update <a href="https://x.com/Shibizens/status/1870792229461074044">highlights</a> the network undergoing a mainnet upgrade.
Among the milestones achieved, it crossed 688 million transactions, peaked to all time high in new total value locked and a maintained 4 million daily transactions volume.
The recent integration with Chainlink is expected to enhance cross-chain functionality, boost on-chain activity and accelerate SHIB burns.
On the Dogecoin front, crypto analyst Ali Martinez highlighted historical patterns where DOGE experienced parabolic rallies after significant retracements. 
For example, DOGE surged thousands of percent following pullbacks in 2017 and 2021. 
In 2024, after a 440% rally and 46% retracement, another explosive move <a href="https://x.com/ali_charts/status/1871097660888813871">could</a> be on the horizon.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42626582/dogecoin-shiba-inu-absent-from-2024s-top-performing-meme-coins-heres-who-made-the-cut">Dogecoin, Shiba Inu Absent From 2024&#8217;s Top-Performing Meme Coins: Here&#8217;s Who Made The Cut</a>
Trader Notes: Altcoin Sherpa sees meme coins performing well but doubts their ability to outperform other crypto assets in the latter half of the market cycle. 
While Dogecoin's brand recognition and Elon Musk's involvement make it unique, Sherpa argues that smaller-cap meme tokens like Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) and Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) might outpace larger-cap memes.
He also <a href="https://x.com/AltcoinSherpa/status/1870504266781302822">suggests</a> big-cap meme coins will likely remain dependent on broader market movements, with a significant rally in Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) potentially lifting memes.
Sherpa concluded that while recognizable tokens like Shiba Inu, Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>), and Dogwifhat will perform decently, they're unlikely to outperform top utility tokens like Aave (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/aave/usd">AAVE</a>), Hyperliquid (CRYPTO: HYPE) and Ethena (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ENA</a>), or trending crypto sectors such as AI-driven projects.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42514226/shiba-inu-burn-rate-surges-3609-as-dogecoin-whales-move-5-8-billion-doge-what-is-going-on">Shiba Inu Burn Rate Surges 3,609% As Dogecoin Whales Move 5.8 Billion DOGE: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AAVE

$DOGE

$ENA

$ETH

$FLOKI

$PEPE

$SHIB

$WIF

Dogecoin, Shiba Inu Could Underperform Stronger Cryptos, Trader Warns: Here's Why

Cartesian Therapeutics ( ($RNAC) ) has provided an update. Cartesian Therapeutics announced promising results from its Phase 2b trial of Descartes-...

Cartesian Therapeutics Reports Promising Phase 2b Trial Results

Cartesian Therapeutics (RNAC) announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized m...

Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia

H.C. Wainwright raised the firm's price target on Cartesian Therapeutics (RNAC) to $45 from $41 and keeps a Buy rating on the shares. The firm says...

Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on UnitedHealth (UNH – Research Report), Cartesian Ther...

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price target of ...

Promising Clinical Developments and Pivotal Trials Position Cartesian Therapeutics for Long-term Success

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), E...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Envista Holdings (NVST) and UnitedHealth (UNH)

16:17 EST Cartesian Therapeutics (RNAC) files to sell 11.39M shares of common stock for holders Published first on TheFly – the ultimate source for...

Cartesian Therapeutics files to sell 11.39M shares of common stock for holders

16:13 EST Cartesian Therapeutics (RNAC) files to sell 6.25M shares of common stock for holders Published first on TheFly – the ultimate source for ...

Cartesian Therapeutics files to sell 6.25M shares of common stock for holders

16:09 EST Cartesian Therapeutics (RNAC) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...

Cartesian Therapeutics files $400M mixed securities shelf

BTIG initiated coverage of Cartesian Therapeutics (RNAC) with a Buy rating and $42 price target Cartesian is pioneering the field of mRNA-based CAR...

Cartesian Therapeutics initiated with a Buy at BTIG

NVST

TERN

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Comments

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga